Design of a Covalent Inhibitor for c-Myc-Dependent Cancers

c-Myc 依赖性癌症的共价抑制剂的设计

• 批准号: 8781047
• 负责人: Jim Wu
• 金额: $ 22.5万
• 依托单位: SUVALENT THERAPEUTICS, INC.
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-07-08 至 2015-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8781047
• 关键词: Address; Advanced Malignant Neoplasm; Animal Model; Binding; Biochemical; Cancer cell line; Cell Death; Cell Line; Cells; Cellular Assay; Clinical; Colorectal Cancer; Development; Disease; Dose; Drug Formulations; Drug Industry; Drug Kinetics; Enzyme Inhibitor Drugs; Enzyme Inhibitors; Enzymes; Funding; Future; Goals; Growth; Human; In Vitro; Laboratories; Lead; Letters; Libraries; Life; MYC gene; Malignant Neoplasms; Medical; Modification; Neoplasm Metastasis; Normal Cell; Normal tissue morphology; Oncogenes; Pathway interactions; Patients; Permeability; Pharmaceutical Chemistry; Pharmaceutical Preparations; Phase; Property; Proteins; Research; Rodent; Small Business Innovation Research Grant; Specificity; Study Section; Therapeutic; Tissues; Toxic effect; Toxicology; Ubiquitin; Xenograft procedure; base; beta catenin; c-myc Genes; cancer cell; cancer therapy; chemical synthesis; design; drug metabolism; effective therapy; high throughput screening; improved; in vivo; inhibitor/antagonist; interest; killings; metastatic colorectal; mouse model; novel; novel therapeutics; oncology; phase 2 study; programs; public health relevance; research and development; scaffold; scale up; small molecule; therapeutic development; therapeutic target; three dimensional structure; transcription factor; tumorigenesis

DESCRIPTION (provided by applicant): The leading commercial goal of our company is to develop novel therapeutics to inhibit the human oncogene, c-Myc. C-Myc is a major human oncogene that is estimated to contribute to at least 70% of all human cancers, most of which are aggressive and respond poorly to current therapies. Despite more than 30 years of research, the development of drugs that inhibit c-Myc has been unsuccessful because the protein is a transcription factor that lacks pockets for small molecules to bind. Therefore, developing novel treatments that inhibit c-Myc is considered one of the most important goals for advancing cancer therapeutics. Recently studies from several laboratories including ours have shown that the small ubiquitin-like modifications (SUMO) are critical for c-Myc-dependent tumorigenesis. Our initial studies are focused on colorectal cancers, because these cancers are almost 100% dependent on c-Myc and new therapies are critically needed for metastatic colorectal cancers to improve patient survival. SUMOylation is important for c-Myc expression through activation of beta-catenin/Tcf-4, the transcription factor for c-Myc expression in colorectal cancers. In preliminary studies, we have identified a very specific and potent inhibitor scaffold of SAE, the activating enzyme that catalyzes SUMO modifications, using high throughput screening. Inhibition of SUMOylation with this inhibitor or by knockdown of SAE dramatically reduced c-Myc level in colorectal cancer cells. We have designed strategies to improve the potency of the lead compound based on our recent discovery of its novel mechanism of action, which indicates a tractable approach to increase its specificity, potency and duration of action. We will then determine the specificity and cellular mechanisms of the improved compounds and will conduct toxicity and efficacy studies in animal models. Our results will significantly advance the field by providing the first proof-of-concept in animal models that SUMOylation is a potential target to inhibit the c-Myc oncogene.

描述（由申请人提供）：我们公司的主要商业目标是开发抑制人类癌基因c-Myc的新型疗法。C-Myc是一种主要的人类致癌基因，据估计至少占所有人类癌症的70%，其中大多数是侵袭性的，对目前的治疗反应很差。尽管有30多年的研究，但抑制c-Myc的药物的开发一直不成功，因为这种蛋白质是一种转录因子，缺乏小分子结合的口袋。因此，开发抑制c-Myc的新疗法被认为是推进癌症治疗的最重要目标之一。最近，包括我们在内的几个实验室的研究表明，小泛素样修饰（SUMO）对c-Myc依赖性肿瘤的发生至关重要。我们最初的研究集中在结直肠癌，因为这些癌症几乎100%依赖于c-Myc，并且转移性结直肠癌迫切需要新的治疗方法来提高患者的生存率。SUMO化通过激活β-连环蛋白/Tcf-4（结肠直肠癌中c-Myc表达的转录因子）对c-Myc表达很重要。在初步研究中，我们已经确定了一个非常具体和有效的抑制剂支架SAE，激活酶催化SUMO修饰，使用高通量筛选。用这种抑制剂抑制SUMO化或通过敲低SAE显著降低结肠直肠癌细胞中的c-Myc水平。基于我们最近发现的新型作用机制，我们设计了提高先导化合物效力的策略，这表明有一种易于处理的方法来提高其特异性、效力和作用持续时间。然后，我们将确定改进化合物的特异性和细胞机制，并在动物模型中进行毒性和功效研究。我们的研究结果将显着推动该领域的发展， 首次在动物模型中证明SUMO化是抑制c-Myc癌基因的潜在靶点。